Kenneth C. Frazier

September 25, 2026

EIKN sees institutional buying following NVIDIA and Merck moves. Institutional investors have increased their purchases of Eikon Therapeutics shares, a trend highlighted in a Benzinga article that points to similar buying activity in NVIDIA and Merck. The move suggests growing confidence in EIKN’s prospects. With the stock trading near its 52‑week low and an RSI of 36.6, the new buying activity could be a sign of potential support at the $9.84 level.

October 16, 2026

Merck Stock Rally Draws Attention to Valuation Concerns. Recent market commentary highlights a renewed confidence in Merck, with analysts debating whether the current rally has priced in too much optimism. While comparisons with peers like AbbVie and Bristol Myers Squibb focus on dividend yields and value, the primary discussion centers on the sustainability of Merck's recent price movement. The stock's high trailing P/E ratio of 112.6 provides context for these valuation concerns, suggesting that investors are closely monitoring if the current momentum can be sustained.